Diabetes/Insulin Resistance

Type 2 diabetes has a huge impact on patient quality of life and healthcare costs. To aid in the public health and clinical efforts to combat the first chronic disease to be declared a global epidemic. Metabolon is developing a practical, fasting blood test that provides a quantitative, tractable measure of glucose metabolism for the patient and physician, as a predictive risk assessment tool for those at-risk for Type 2 diabetes. This diagnostic solution is named Quantose™.

According to the Centers for Disease Control and Prevention (CDC), 25.8 million children and adults in the U.S., or 8.3% of the population, have diabetes. While an estimated 18.8 million have been diagnosed with Type 2 diabetes, approximately 7 million are unaware they have the disease. Based on glycemic measures from 2005-2008, the CDC reported that 35% of the U.S. adult population had pre-diabetes, yielding an estimated 79 million U.S. adults at risk for developing Type 2 diabetes. With the total annual cost associated with diabetes treatment at $174 billion (2007) in the U.S. alone, preventing and managing diabetes and its complications represents global public health challenges and priorities for healthcare systems.*

With costly diabetic complications including cardiovascular disease, retinopathy, neuropathy, and nephropathy, significant unmet medical needs exist in both detecting and risk-stratifying patients who are at high risk for progressing to Type 2 diabetes, as well as determining appropriate therapy and predicting long-term outcomes in the diabetes setting.

Using its metabolomics-driven biomarker discovery platform, Metabolon has discovered a number of significant biochemical markers indicative of risk for Type 2 diabetes. These markers are currently being incorporated in the development of the Quantose™ series of diagnostic products. The first-generation Quantose™ product is a diagnostic test for better identifying high-risk, insulin-resistant patients and predicting their risk of progression to Type 2 diabetes, above and beyond traditional risk factors and glycemic tests. The validated test is currently being offered in Metabolon’s CLIA laboratory as Investigational Use Only. The Quantose™ product applications will be targeted at different stages of the Type 2 diabetes continuum, pre-diabetes and therapeutic monitoring, with the goal of increasing effectiveness of preventing the disease and its complications.

*Reference: Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and pre-diabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011;
http://www.cdc.gov/diabetes/pubs/references11.htm